Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142753 · ClinicalTrials.gov registry record · Phase 4
Immunologic Memory (Supp. of ATN 024)
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 4
- Development phase
- 95
- Enrollment target
NCT00142753 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 95 participants.
The verdict
NCT00142753, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 95 participants
- Enrollment target
Study Summary
This is an exploratory, laboratory-based evaluation of cellular immune response to immunization with hepatitis B surface antigen in HIV-infected and HIV-uninfected adolescents. This is a substudy of ATN 024 and ATN 025. This substudy will compare cellular immune response in responders and nonresponders to immunization and also evaluate the relationship of these factors to the persistence of known correlates of serologic protection for the hepatitis B virus.
Interventions
- BIOLOGICAL Engerix B
- BIOLOGICAL Twinrix for ATN 024
- BIOLOGICAL Recombivax
- BIOLOGICAL Twinrix for ATN 025
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142753
The ClinicalTrials.gov registry entry for NCT00142753 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Engerix B is the first listed.
NCT00142753 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142753 about?
NCT00142753 is a clinical study titled "Immunologic Memory (Supp. of ATN 024)". This is an exploratory, laboratory-based evaluation of cellular immune response to immunization with hepatitis B surface antigen in HIV-infected and HIV-uninfected adolescents. This is a substudy of ATN 024 and ATN 025. This substudy will compare cellular immune response in responders and nonrespond...
What is the current status of trial NCT00142753?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 95 participants. The study started on 2005-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00142753?
The interventions under investigation include: Engerix B (BIOLOGICAL), Twinrix for ATN 024 (BIOLOGICAL), Recombivax (BIOLOGICAL), Twinrix for ATN 025 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00142753?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.